Drug Trial Radar · NCT04519749
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Sep 1, 2020
Primary completion
Jan 2026
Study completion Jun 2030
Sponsor
- Lead sponsor
- 4D Molecular TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.
Conditions
- Fabry Disease
Interventions
4D-310Biological
4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse eventsTime frame: 1 year
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of California at San Diego
La Jolla, California
Emory University
Atlanta, Georgia
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Lysosomal & Rare Disorders Research & Treatment Center, Inc
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.